Acolbifene (ACOL) is a fourth-generation
selective estrogen receptor modulator (
SERM) that has strong and pure antiestrogenic properties toward
estrogen-sensitive
cancers, but improves energy and lipid metabolism in an
estrogen-like fashion in rodent models. The aim of this study was to determine the potency of ACOL to reduce cholesterolemia in a dietary model of
hypercholesterolemia and to establish its mechanisms of action. Intact and ovariectomized (OVX) female rats were treated for 3 weeks with ACOL, and serum
cholesterol and liver determinants of
cholesterol metabolism were assessed.
Acolbifene prevented both diet- and
ovariectomy-induced
weight gain and completely prevented diet-induced
hypercholesterolemia. Relative to a reference chow diet, the high-
cholesterol diet decreased the
high-density lipoprotein (
HDL) cholesterol fraction, which remained unaffected by ACOL, indicating that in hypercholesterolemic conditions, ACOL modulated only the non-HDL fraction. No impact of ACOL on determinants of liver
cholesterol synthesis was observed. In contrast, ACOL increased hepatic
low-density lipoprotein receptor protein in both intact and OVX rats, which was negatively correlated with serum total and non-
HDL cholesterol (r=-0.59, P<.0001), suggesting a contribution of receptor-mediated hepatic uptake of
cholesterol-rich
lipoproteins to the hypocholesterolemic effect of ACOL. These findings establish that ACOL retains its powerful
cholesterol-lowering action in diet-induced
hypercholesterolemia and suggest that the
SERM acts in such conditions through favoring hepatic
low-density lipoprotein receptor-mediated uptake of
cholesterol transported by non-HDL
lipoprotein fractions.